Acurx Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

ISSUANCE OF EQUITY INTERESTS (Details)

ISSUANCE OF EQUITY INTERESTS (Details)											1 Months Ended	12 Months Ended
ISSUANCE OF EQUITY INTERESTS (Details)	Aug. 04, 2025	Jun. 20, 2025 USD ($) $ / shares shares	Jun. 17, 2025 USD ($) $ / shares shares	May 08, 2025 USD ($) $ / shares shares	Mar. 06, 2025 USD ($) $ / shares shares	Jan. 06, 2025 USD ($) $ / shares shares	Nov. 15, 2023 USD ($)	May 18, 2023 USD ($) shares	Jul. 27, 2022 USD ($) shares	Jun. 29, 2021 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 shares	Sep. 22, 2025 shares	Sep. 21, 2025 shares	Jun. 23, 2021 $ / shares shares
Equity
Reverse stock split conversion ratio	0.05
Common stock, authorized (in shares)												250,000,000	200,000,000		250,000,000	200,000,000	250,000,000
Common stock par value (in dollars per share) \| $ / shares												$ 0.001	$ 0.001				$ 0.001
Common stock, Issued (in shares)												2,348,113	851,534
Common stock, outstanding (in shares)												2,348,113	851,534
Preferred stock, shares authorized (in shares)												10,000,000	10,000,000				10,000,000
Preferred stock, par value \| $ / shares												$ 0.001	$ 0.001				$ 0.001
Preferred stock, shares outstanding (in shares)												0	0
Shares issued (in shares)								30,093	57,961	143,750
Share sales price (in dollars per share) \| $ / shares										$ 120
Proceeds from stock issue \| $								$ 4,000,000	$ 4,200,000	$ 17,300,000
Warrants exercised (in shares)												422,090
Proceeds from Warrant Exercise \| $												$ 1,360,544	$ 210,199
Affiliate Investors \| Series B warrants
Equity
Warrants exercised (in shares)											2,961
Proceeds from Warrant Exercise \| $											$ 200,000
Underwriter option \| Series E warrants
Equity
Shares issued (in shares)						7,389
Warrant exercise price (in dollars per share) \| $ / shares						$ 25.38
Fair value of Warrants \| $						$ 85,419
Underwriter option \| Series F warrants
Equity
Shares issued (in shares)					8,235
Warrant exercise price (in dollars per share) \| $ / shares					$ 10
Fair value of Warrants \| $					$ 56,163
Underwriter option \| Measurement Input, Expected Term \| Series E warrants
Equity
Warrants term						5 years
Underwriter option \| Measurement Input, Expected Term \| Series F warrants
Equity
Warrants term					5 years
Underwriter option \| Measurement Input, Risk Free Rate \| Series E warrants
Equity
Measurement Input, Warrants						4.46
Underwriter option \| Measurement Input, Risk Free Rate \| Series F warrants
Equity
Measurement Input, Warrants					3.98
Underwriter option \| Measurement Input, Share Price \| Series E warrants
Equity
Measurement Input, Warrants						16.2
Underwriter option \| Measurement Input, Share Price \| Series F warrants
Equity
Measurement Input, Warrants					9
Underwriter option \| Measurement Input, Volatility \| Series E warrants
Equity
Measurement Input, Warrants						102
Underwriter option \| Measurement Input, Volatility \| Series F warrants
Equity
Measurement Input, Warrants					102
January 2025 Registered Direct Offering
Equity
Shares issued (in shares)						123,153
Share sales price (in dollars per share) \| $ / shares						$ 20.3
Proceeds from stock issue \| $						$ 2,500,000
Net proceeds stock issuance \| $						$ 2,100,000
January 2025 Registered Direct Offering \| Series E warrants
Equity
Shares issued (in shares)						123,153
Warrant exercise price (in dollars per share) \| $ / shares						$ 18
Warrants term						5 years
January 2025 Registered Direct Offering \| Affiliate Investors
Equity
Shares issued (in shares)						8,374
January 2025 Registered Direct Offering \| Affiliate Investors \| Series E warrants
Equity
Shares issued (in shares)						8,374
January 2025 Registered Direct Offering \| Investor
Equity
Shares issued (in shares)						114,779
January 2025 Registered Direct Offering \| Investor \| Series E warrants
Equity
Shares issued (in shares)						114,779
March 2025 Registered Direct Offering
Equity
Shares issued (in shares)					107,500
Share sales price (in dollars per share) \| $ / shares					$ 8
Proceeds from stock issue \| $					$ 1,100,000
Net proceeds stock issuance \| $					$ 900,000
March 2025 Registered Direct Offering \| Pre-funded warrants
Equity
Shares issued (in shares)					29,750
Warrant exercise price (in dollars per share) \| $ / shares					$ 7.998
March 2025 Registered Direct Offering \| Series F warrants
Equity
Shares issued (in shares)					411,750
Warrant exercise price (in dollars per share) \| $ / shares					$ 8
Warrants term					24 months
At the Market Offering
Equity
Aggregate offering price \| $							$ 17,000,000						$ 7,800,000
Sale agent commission rate							3.00%
Shares issued (in shares)													106,610	894
Share sales price (in dollars per share) \| $ / shares													$ 62
Proceeds from stock issue \| $													$ 6,600,000
Net proceeds stock issuance \| $													$ 6,400,000
Equity Line of Credit Purchase Agreement
Equity
Shares issued (in shares)				751,397
Share sales price (in dollars per share) \| $ / shares				$ 5.26
Proceeds from stock issue \| $				$ 3,953,430
Aggregate value of shares committed for purchase \| $				12,000,000
Net proceeds stock issuance \| $				$ 3,808,439
Equity Line of Credit Purchase Agreement \| Lincoln Park Capital Fund
Equity
Shares issued (in shares)				44,963
Non-cash issuance costs of ELOC agreement \| $				$ 360,000
Warrant Inducement Agreement
Equity
Proceeds from stock issue \| $			$ 2,700,000
Number of shares called by Warrant			222,272
Net proceeds stock issuance \| $			$ 2,500,000
Proceeds from Warrant Exercise \| $			$ 2,700,000
Warrant exercise price (in dollars per share) \| $ / shares			$ 12
Warrant Inducement Agreement \| Series A warrants
Equity
Number of shares called by Warrant			61,538
Warrant exercise price (in dollars per share) \| $ / shares			$ 65
Warrant Inducement Agreement \| Series B warrants
Equity
Number of shares called by Warrant			27,400
Warrant exercise price (in dollars per share) \| $ / shares			$ 65
Warrant Inducement Agreement \| Series C warrants
Equity
Number of shares called by Warrant			66,667
Warrant exercise price (in dollars per share) \| $ / shares			$ 65.2
Warrant Inducement Agreement \| Series D warrants
Equity
Number of shares called by Warrant			66,667
Warrant exercise price (in dollars per share) \| $ / shares			$ 65.2
Warrant Inducement Agreement \| Series G Warrants
Equity
Non-cash equity issuance costs \| $		$ 4,527,245
Warrant exercise price (in dollars per share) \| $ / shares			$ 8.5
Warrant Inducement Agreement \| Series G-1 Warrants
Equity
Shares issued (in shares)			311,180
Warrants term			5 years
Warrant Inducement Agreement \| Series G-2 Warrants
Equity
Shares issued (in shares)			133,363
Warrants term			5 years
Warrant Inducement Agreement \| H.C. Wainwright & Co.
Equity
Percentage of private placement offerings warrant coverage		7.00%
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Underwriter's Warrants
Equity
Shares issued (in shares)		13,336
Warrant exercise price (in dollars per share) \| $ / shares		$ 15
Fair value of Warrants \| $		$ 109,624
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Expected Term \| Underwriter's Warrants
Equity
Warrants term		5 years
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Risk Free Rate \| Underwriter's Warrants
Equity
Measurement Input, Warrants		3.96
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Share Price \| Underwriter's Warrants
Equity
Measurement Input, Warrants \| $ / shares		11
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Volatility \| Underwriter's Warrants
Equity
Measurement Input, Warrants		105